Similar articles

• Psychopharmacologic applications to cancer. An overview.

  Derogatis LR. Derogatis LR. Cancer. 1982 Nov 1;50(9 Suppl):1962-7. doi: 10.1002/1097-0142(19821101)50:9+<1962::aid-cncr2820501311>3.0.co;2-c. Cancer. 1982. PMID: 7127273 No abstract available.
• A survey of psychotropic drug utilization by patients with advanced neoplastic disease.

  Jaeger H, Morrow GR, Carpenter PJ, Brescia F. Jaeger H, et al. Gen Hosp Psychiatry. 1985 Oct;7(4):353-60. doi: 10.1016/0163-8343(85)90051-9. Gen Hosp Psychiatry. 1985. PMID: 4065552
• Psychotropic medications in patients with cancer.

  Peterson LG, Leipman M, Bongar B. Peterson LG, et al. Gen Hosp Psychiatry. 1987 Sep;9(5):313-23. doi: 10.1016/0163-8343(87)90062-4. Gen Hosp Psychiatry. 1987. PMID: 3315844 Review.
• Residual symptoms in depression: can treatment be symptom-specific?

  Menza M, Marin H, Opper RS. Menza M, et al. J Clin Psychiatry. 2003 May;64(5):516-23. doi: 10.4088/jcp.v64n0504. J Clin Psychiatry. 2003. PMID: 12755653 Review.
• Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network.

  Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P; Research Steering Committee of the EAPC. Laugsand EA, et al. J Opioid Manag. 2009 Jan-Feb;5(1):11-21. doi: 10.5055/jom.2009.0002. J Opioid Manag. 2009. PMID: 19344044